Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed outlook. Financials show a stable cash position with a runway until Q3 2025, but high cash usage raises financial sustainability concerns. Clinical developments are promising, particularly in mCRC and ovarian cancer, yet regulatory and competitive risks loom large. The Q&A session reveals steady trial enrollment and strategic partnerships, but lacks clarity on scientific validation. Overall, the balance of positive clinical updates and financial/market risks suggests a neutral stock price movement in the near term.
Key Financial Performance
Cash and short-term investments $60.3 million, no year-over-year change mentioned.
Cash used in operating activities $9.2 million in Q2 2024, no year-over-year change mentioned.
Cash runway Current cash resources provide runway through the end of Q3 2025, updated from previous guidance of runway into Q3 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Onvansertib in mCRC: Cardiff Oncology is actively enrolling patients in the CRDF-004 trial for RAS-mutated metastatic colorectal cancer (mCRC), with plans to release initial data later this year.
Onvansertib in PDAC: The company is shifting its focus to support a first-line investigator-initiated trial combining onvansertib with NALIRIFOX for metastatic pancreatic ductal adenocarcinoma (PDAC), following the approval of NALIRIFOX as the new standard of care.
Onvansertib in Ovarian Cancer: Preclinical data shows onvansertib's potential in overcoming resistance to PARP inhibitors in ovarian cancer, with promising results published in a peer-reviewed journal.
Cash Position: As of June 30, 2024, Cardiff Oncology reported cash and short-term investments totaling $60.3 million, with an updated cash runway guidance extending through the end of Q3 2025.
Clinical Development Strategy: The company emphasizes confidence in its clinical development strategy for RAS-mutated mCRC and anticipates a significant impact on treatment paradigms.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements risks: The company acknowledges that forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from anticipated outcomes.
Regulatory risks: The company refers to the Risk Factors section in its annual report, indicating potential regulatory challenges that could impact its operations.
Clinical trial risks: The ongoing CRDF-004 trial may face challenges in patient enrollment and execution, which could affect the timeline for data readouts.
Competitive pressures: The approval of NALIRIFOX for first-line metastatic PDAC introduces competitive pressures, necessitating a shift in the company's PDAC program.
Financial risks: The company reported cash used in operating activities of $9.2 million in Q2 2024, which raises concerns about financial sustainability and the need for future funding.
Market risks: The company operates in a highly competitive and regulated market, which poses risks related to market acceptance and the success of its therapies.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
CRDF-004 Trial: Ongoing Phase II trial evaluating onvansertib in combination with standard of care for RAS-mutated mCRC, currently active in 33 sites with plans to enroll 90 patients.
Pancreatic Cancer Program: Transitioning to support a first-line investigator-initiated trial combining onvansertib with NALIRIFOX after the approval of NALIRIFOX for first-line metastatic PDAC.
Ovarian Cancer Research: Continued preclinical studies showing onvansertib's potential in overcoming resistance to PARP inhibitors in ovarian cancer.
Cash and Short-term Investments: As of June 30, 2024, totaled $60.3 million.
Cash Used in Operating Activities: $9.2 million in Q2 2024.
Cash Runway Guidance: Current cash resources provide runway through the end of Q3 2025, updated from previous guidance.
Data Readout Expectations: Initial data readout for CRDF-004 trial expected later this year, including objective response rate data for approximately half of the enrolled patients.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Cash and short-term investments: $60.3 million as of June 30, 2024.
Cash used in operating activities: $9.2 million in Q2 2024.
Cash runway guidance: Current cash resources provide runway through the end of the third quarter of 2025.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Has the enrollment in the 004 trial held steady over the summer or seen acceleration?
A:Enrollment is tracking quite well and is tracking with our guidance of having an initial look at the data later this year. We have Pfizer Ignite as a strong partner, which has helped drive the enrollment.
Q:Why be aggressive on adopting NALIRIFOX for the initial proof of concept in pancreatic cancer?
A:We have good data from combining onvansertib with 3 of the 4 chemo agents in second line. We also show good tolerability of onvansertib with these agents, and oxaliplatin does not have overlapping toxicities with onvansertib.
Q:Can you comment on the level of scientific validation with the change of the IST in pancreatic cancer?
A:The irinotecan synergy is a main reason for going with the combination with NALIRIFOX in first line. The TI has experience in our second-line pancreatic trial and is enthusiastic about going into first line.
Q:Are you planning to do any sort of combinatorial work in the ADC field for ovarian cancer?
A:We are currently preclinically looking at ADCs in combination with onvansertib, exploring that in several areas where ADCs have been approved.
Q:Review of Unclear Management Responses
A:No direct answers were avoided, but some responses lacked specific data or details, particularly regarding the adoption of NALIRIFOX and the scientific validation of the IST.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ADC
ADCs
CRDF Phase
Gem Abraxane
II trial
Ib II
Kiki Patel
NALIRIFOX line
PARP inhibitor
PDAC
Phase II
Phase Ib
RAS mCRC
agenda
area
cancer indication
chemo agent
chemotherapy
combination onvansertib
drug
item
kind enrollment
onvansertib NALIRIFOX
onvansertib combination
onvansertib olaparib
onvansertib standard
potential treatment
regimen
site patient
study onvansertib
totality
treatment paradigm
trial onvansertib
type
update cancer
CRDF Transcript
Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript
Unknown2-27
The earnings call presents a balanced picture. Financially, the company shows a solid cash position and runway, but faces risks from regulatory changes and market competition. The Q&A reveals positive clinical progress but lacks clarity on timelines, which could concern investors. The $40 million capital raise is a positive, but the absence of specific guidance and potential delays in trials offset this. Overall, the sentiment is neutral as positives are balanced by uncertainties and risks.
Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript
Unknown8-10
The earnings call summary presents a mixed outlook. Financials show a stable cash position with a runway until Q3 2025, but high cash usage raises financial sustainability concerns. Clinical developments are promising, particularly in mCRC and ovarian cancer, yet regulatory and competitive risks loom large. The Q&A session reveals steady trial enrollment and strategic partnerships, but lacks clarity on scientific validation. Overall, the balance of positive clinical updates and financial/market risks suggests a neutral stock price movement in the near term.
Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript
Unknown5-3
The earnings call presents a mixed outlook. While Cardiff Oncology shows promise with its first-line RAS-mutated mCRC trial and a solid cash runway into Q3 2025, delays in enrollment and reliance on Pfizer Ignite pose risks. The Q&A revealed confidence in trial execution but also highlighted uncertainties, such as the delay in data readouts and lack of diversification into RAS wild-type mCRC. The financial position is stable, but the lack of new revenue streams or shareholder return plans tempers optimism. Overall, the sentiment is neutral, with potential for both positive and negative developments.
Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings Call Transcript
Unknown3-1
The earnings call indicates a neutral sentiment. While the company has a solid cash runway and a promising partnership with Pfizer Ignite, there are significant risks, including clinical and regulatory challenges, high cash burn, and safety concerns. The Q&A revealed some hesitancy from management to provide detailed responses, which may raise investor concerns. Although there is potential for positive developments, the lack of immediate catalysts and the uncertainties surrounding trial outcomes and market differentiation suggest a neutral stock price movement in the near term.
CRDF Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
